youtube_live
Q3 2026 earnings • 8:00 AM tomorrow
See detailschevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
$31.38
arrow_upward
+0.58%(+0.18) 1D
$31.38
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 4, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
$32.09
High
$32.09
Low
$30.56
Mkt. cap
1.87B
Avg. vol.
1.24M
Volume
1.11M
52-wk high
$45.99
52-wk low
$22.24
EPS
-$7.01
Beta
0.66
Shares outstanding
59.70M
No. of employees
540
Open
$32.09
High
$32.09
Low
$30.56
Mkt. cap
1.87B
Avg. vol.
1.24M
Volume
1.11M
52-wk high
$45.99
52-wk low
$22.24
EPS
-$7.01
Beta
0.66
Shares outstanding
59.70M
No. of employees
540
News stories
From web sources and news partners
Investing.com
·
8 hours ago
Agios earnings ahead: Can thalassemia offset drug delay?
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc